Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 670
  • Home
  • Print this page
  • Email this page

    Article Cited by others

REVIEW ARTICLE

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines

Trinh Saralinh, Le Alex, Gowani Sajida, La-Beck Ninh M

Year : 2019| Volume: 6| Issue : 2 | Page no: 154-160

   This article has been cited by
 
1 Angioedema late in the course of adjuvant nivolumab therapy for melanoma
Atul Ratra,Constantin A Dasanu
Journal of Oncology Pharmacy Practice. 2020; 26(4): 1019
[Pubmed]  [Google Scholar] [DOI]
2 Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Massimo Ralli,Andrea Botticelli,Irene Claudia Visconti,Diletta Angeletti,Marco Fiore,Paolo Marchetti,Alessandro Lambiase,Marco de Vincentiis,Antonio Greco
Journal of Immunology Research. 2020; 2020: 1
[Pubmed]  [Google Scholar] [DOI]
3 Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
Pak Yui Fong,Shing Chuen Chow,Bernard Ming Hong Kwong,Charlene Cheuk Lam Lau,Christy Yik Ching Lau,Athena Hoi Ting Lee,Ha Ying Nip,Cheuk Yin Wong,Benedict Tsz Hin Yan,Ho Yin Chung
Journal of Clinical Rheumatology and Immunology. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
4 Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
Maria V. Deligiorgi,Gerasimos Siasos,Chrysovalantis Vergadis,Dimitrios T. Trafalis
International Immunopharmacology. 2020; 83: 106427
[Pubmed]  [Google Scholar] [DOI]
5 Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer
Ninh M. La-Beck,Dung T. Nguyen,Alex D. Le,Saeed K. Alzghari,Saralinh T. Trinh
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
Lillian Sun,Joshua Arbesman,Melissa Piliang
Archives of Dermatological Research. 2020;
[Pubmed]  [Google Scholar] [DOI]
7 Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians
Maria V Deligiorgi,Mihalis I Panayiotidis,Dimitrios T Trafalis
Immunotherapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
8 Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review
Taylor Halsey,Gabriel Ologun,Jennifer Wargo,Robert R. Jenq
Seminars in Hematology. 2020;
[Pubmed]  [Google Scholar] [DOI]
9 Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
Andrea Pagan,Yadis M Arroyo-Martinez,Ankita Tandon,Carlos Bertran-Rodriguez,Jeffrey Gill
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
10 Cancer immunotherapy–related adverse events: causes and challenges
Ada G. Blidner,Jennifer Choi,Tim Cooksley,Michael Dougan,Ilya Glezerman,Pamela Ginex,Monica Girotra,Dipti Gupta,Douglas Johnson,Vickie R. Shannon,Maria Suarez-Almazor,Bernardo L. Rapoport,Ronald Anderson
Supportive Care in Cancer. 2020;
[Pubmed]  [Google Scholar] [DOI]
11 Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass
Nayson L Fernandes,Soujanya Sodavarapu,Sukhmine Nedopil,Nikita Mohapatra,Dinesh Vyas
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
12 Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs
Tyler C. Vandivort,David B. Horton,Steven B. Johnson
Journal of Clinical and Translational Science. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
13 Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma
Katarina Hradska,Michal Kascak,Roman Hajek,Tomas Jelinek
Expert Review of Hematology. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
14 Immune-Mediated Toxic Epidermal Necrolysis
Dinesh Keerty,Viktoriya Koverzhenko,Dalila Belinc,Katie LaPorta,Elizabeth Haynes
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
15 Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy
Dinesh Keerty,Manoj Das,Julie Hallanger-Johnson,Elizabeth Haynes
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
16 Atypical extended immune-related neutropenia in patient treated with pembrolizumab
Pierre-Antoine Laurain,Térence Landrin,Sami Souidi,Philippe Beuzeboc,Florian Scotté
European Journal of Cancer. 2020;
[Pubmed]  [Google Scholar] [DOI]
17 Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use
Rebecca N. Jerome,Meghan Morrison Joly,Nan Kennedy,Jana K. Shirey-Rice,Dan M. Roden,Gordon R. Bernard,Kenneth J. Holroyd,Joshua C. Denny,Jill M. Pulley
Drug Safety. 2020;
[Pubmed]  [Google Scholar] [DOI]
18 Classical Examples of the Concept of the ASIA Syndrome
Vânia Borba,Anna Malkova,Natalia Basantsova,Gilad Halpert,Laura Andreoli,Angela Tincani,Howard Amital,Yehuda Shoenfeld
Biomolecules. 2020; 10(10): 1436
[Pubmed]  [Google Scholar] [DOI]
19 Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
Rhiane Moody,Kirsty Wilson,Anthony Jaworowski,Magdalena Plebanski
Cancers. 2020; 12(3): 673
[Pubmed]  [Google Scholar] [DOI]
20 Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event
Maria V. Deligiorgi,Dimitrios T. Trafalis
International Immunopharmacology. 2020; 89: 107050
[Pubmed]  [Google Scholar] [DOI]
21

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date

Iris Y Sheng,Moshe C Ornstein
Cancer Management and Research. 2020; Volume 12: 4871
[Pubmed]  [Google Scholar] [DOI]
22 Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Omid Kooshkaki,Afshin Derakhshani,Negar Hosseinkhani,Mitra Torabi,Sahar Safaei,Oronzo Brunetti,Vito Racanelli,Nicola Silvestris,Behzad Baradaran
International Journal of Molecular Sciences. 2020; 21(12): 4427
[Pubmed]  [Google Scholar] [DOI]
23 Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Silvia Vivarelli,Luca Falzone,Caterina Maria Grillo,Giuseppa Scandurra,Francesco Torino,Massimo Libra
Cancers. 2020; 12(8): 2237
[Pubmed]  [Google Scholar] [DOI]
24 Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers
Tomomi W Nobashi,Yuko Nishimoto,Yujiro Kawata,Hidetaka Yutani,Masaki Nakamura,Yuichi Tsuji,Atsushi Yoshida,Akihiko Sugimoto,Takayuki Yamamoto,Israt S Alam,Satoshi Noma
The British Journal of Radiology. 2020; : 20200409
[Pubmed]  [Google Scholar] [DOI]
25 Management of immune checkpoint inhibitor-related rheumatic adverse events
Jiaxin Zhou,Hanping Wang,Xiaoxiao Guo,Qian Wang,Lian Duan,Xiaoyan Si,Li Zhang,Xiaowei Liu,Yue Li,Wen Zhang,Li Zhang
Thoracic Cancer. 2019;
[Pubmed]  [Google Scholar] [DOI]
26 Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Ronald Anderson,Annette J. Theron,Bernardo L. Rapoport
Frontiers in Immunology. 2019; 10
[Pubmed]  [Google Scholar] [DOI]
27 Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report
El Ali Ziad,Verset Laurine
Clinical Oncology and Research. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
28 Durvalumab in cancer medicine: a comprehensive review
Juliana Alvarez-Argote,Constantin A. Dasanu
Expert Opinion on Biological Therapy. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
29 The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Danilo Rocco,Luigi Della Gravara,Ciro Battiloro,Cesare Gridelli
Expert Review of Anticancer Therapy. 2019; 19(7): 561
[Pubmed]  [Google Scholar] [DOI]

 

Read this article